ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Phenomapping Reveals High-Risk HeF.rEF Subgroups 10/09/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded October 09, 2025. This episode summarizes 5 key cardiology studies on topics like risk prediction model and cardiovascular death. Key takeaway: Phenomapping Reveals High-Risk HeF.rEF Subgroups.
Article Links:
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. (Journal of cardiac failure)
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. (JAMA cardiology)
Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. (JAMA cardiology)
Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/
Featured Articles
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061873
Summary: heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061917
Summary: This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41060665
Summary: This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.
Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41060636
Summary: This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual’s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.
Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41058565
Summary: This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes.
Transcript
Today’s date is October 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. HOPE for children: successful pediatric D.C.D. heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.
Article number two. Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.
Article number three. Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.
Article number four. Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual’s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.
Article number five. Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes.
Thank you for listening. Don’t forget to subscribe.
Keywords
risk prediction model, cardiovascular death, care delivery model, Heart Failure with Reduced Ejection Fraction, genetic variants, monogenic risk, residual risk, transesophageal echocardiography, heart failure hospitalizations, thrombus screening, symptom burden, interprofessional care, palliative care, advanced heart disease, hypothermic oxygenated perfusion, thromboembolic events, Donation after Circulatory Death, pediatric heart transplantation, phenomapping, advanced heart failure, polygenic risk, intracardiac echocardiography, donor organ preservation, atrial fibrillation ablation, atrial fibrillation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Phenomapping Reveals High-Risk HeF.rEF Subgroups 10/09/25 first appeared on Cardiology Today.
Article Links:
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. (Journal of cardiac failure)
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. (JAMA cardiology)
Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. (JAMA cardiology)
Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/phenomapping-reveals-high-risk-hef-ref-subgroups-10-09-25/
Featured Articles
Article 1: HOPE for children: successful pediatric DCD heart transplantation using hypothermic oxygenated perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061873
Summary: heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.
Article 2: Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations.
Journal: Journal of cardiac failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41061917
Summary: This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.
Article 3: Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41060665
Summary: This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.
Article 4: Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41060636
Summary: This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual’s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.
Article 5: Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41058565
Summary: This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes.
Transcript
Today’s date is October 09, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. HOPE for children: successful pediatric D.C.D. heart transplantation using hypothermic oxygenated perfusion. This article describes the successful clinical adoption of hypothermic oxygenated perfusion (H.O.P.E.) for pediatric Donation after Circulatory Death (D.C.D.) heart transplantation in the U.K. and Belgium. This innovative approach aims to address the increasing demand for pediatric heart transplants and the high waiting list mortality in children with advanced heart failure. While the full clinical outcome data are not detailed, the method is presented as successfully implemented, allowing for an expansion of the donor pool for life-saving pediatric transplantation. This represents a significant advancement towards improving access to organ transplantation for pediatric patients.
Article number two. Implementing HeartPal: Design and Early Results of a Specialized Care Delivery Model for Advancing Palliative Care in Advanced Heart Disease Populations. This article details the design, implementation, and early outcomes of HeartPal, an interprofessional palliative care service embedded within an advanced heart disease program. Launched in 2019, HeartPal utilizes a team including a nurse practitioner, social worker, and palliative care physician to deliver longitudinal care across inpatient and outpatient settings. Early results indicate the feasibility and potential effectiveness of this specialty-aligned model in addressing high symptom burden and complex care decisions for patients with advanced heart disease. This embedded approach may serve as a replicable model to improve palliative care access within cardiology.
Article number three. Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial. This multicenter randomized clinical trial was conducted to determine if Intracardiac Echocardiography (I.C.E.) is noninferior to Transesophageal Echocardiography (T.E.E.) for thrombus screening prior to atrial fibrillation ablation. The study, conducted across 10 hospitals in China, aimed to assess whether I.C.E. could offer comparable safety in preventing periprocedural thromboembolic events, potentially with procedural advantages over T.E.E. While the abstract does not provide the specific clinical outcomes, the trial design focuses on a critical safety aspect of atrial fibrillation ablation, with results pending to inform future imaging guidance strategies.
Article number four. Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. This cohort study, utilizing whole-genome sequence data from participants of the U.K. Biobank, examined the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to the incidence of atrial fibrillation. The researchers successfully developed an integrated genomic model for atrial fibrillation (I.G.M.-A.F.) for improved risk prediction. Key findings elucidate the complex genetic architecture of atrial fibrillation, demonstrating that incorporating these diverse genetic components significantly enhances the ability to predict an individual’s risk for developing the condition. This advancement offers a more comprehensive understanding of atrial fibrillation pathophysiology and holds promise for precision medicine.
Article number five. Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy. This V.I.C.T.O.R.I.A. substudy used multimodality data, including clinical, electrocardiographic (E.C.G.), echocardiographic, biomarker, and targeted proteomics data, to identify unique Heart Failure with Reduced Ejection Fraction (HeF.rEF) subpopulations with high residual risk. Through agglomerative hierarchical clustering, the study successfully identified distinct patient subgroups that remain at elevated risk for heart failure hospitalizations and cardiovascular death despite current therapies. These findings highlight the heterogeneity within the Heart Failure with Reduced Ejection Fraction population and underscore the need for more tailored, risk-stratified management strategies to improve outcomes.
Thank you for listening. Don’t forget to subscribe.
Keywords
risk prediction model, cardiovascular death, care delivery model, Heart Failure with Reduced Ejection Fraction, genetic variants, monogenic risk, residual risk, transesophageal echocardiography, heart failure hospitalizations, thrombus screening, symptom burden, interprofessional care, palliative care, advanced heart disease, hypothermic oxygenated perfusion, thromboembolic events, Donation after Circulatory Death, pediatric heart transplantation, phenomapping, advanced heart failure, polygenic risk, intracardiac echocardiography, donor organ preservation, atrial fibrillation ablation, atrial fibrillation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Phenomapping Reveals High-Risk HeF.rEF Subgroups 10/09/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust